Erratum to: Toxicogenomics of nanoparticulate delivery of etoposide: Potential impact on nanotechnology in retinoblastoma therapy (Cancer Nano, 10.1007/s12645-010-0010-4);Toxicogenomics of nanoparticulate delivery of etoposide: Potential impact on nanotechnology in retinoblastoma therapy

Cancer Nanotechnology

Volumn 2, Issue 1-6, 2011, Pages 21-36

  Mitra, Moutushy ^a,d   Dilnawaz, Fahima ^b   Misra, Ranjita ^b   Harilal, Anju ^a   Verma, Rama Shenkar ^c   Sahoo, Sanjeeb K ^b   Krishnakumar, Subramanian ^a  

^a VISION RESEARCH FOUNDATION   (India)

^b INSTITUTE OF LIFE SCIENCES   (India)

^c INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

^d SASTRA UNIVERSITY   (India)

Author keywords

Apoptosis; Gene expression; Ocular drug delivery; PLGA nanoparticles; Retinoblastoma

Indexed keywords

ETOPOSIDE; NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG UPTAKE; FLOW CYTOMETRY; GENE ACTIVITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; MICROARRAY ANALYSIS; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RETINOBLASTOMA; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; TOXICOGENETICS; ZETA POTENTIAL;

EID: 81555209727     PISSN: 18686958     EISSN: 18686966     Source Type: Journal    
DOI: 10.1007/s12645-011-0013-9     Document Type: Erratum

References (66)

1. Abramson DH, Servodidio CA, Nissen M (1998) Treatment of retinoblastoma with the transscleral diode laser. Am J Ophthalmol 126: 733-735.
2. Abramson DH, Beaverson K, Sangani P, Vora RA, Lee TC, Hochberg HM, Kirszrot J, Ranjithan M (2003) Screening for retinoblastoma: presenting signs as prognosticators of patients and ocular survival. Pediatrics 112: 1248-1255.
3. Acharya SDF, Sahoo SK (2009) Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 30: 5737-5750.
4. Amendola BE, Lamm FR, Markoe AM, Karlsson UL, Shields J, Shields CL, Augsburger J, Brady LW, Woodleigh R, Miller C (2006) Radiotherapy of retinoblastoma: a review of 63 children treated with different irradiation techniques. Cancer 66: 21-26.
5. Ashley DM, Meier L, Kerby T, Zalduondo FM, Friedman HS, Gajjar A, Kun L, Duffner PK, Smith S, Longee D (1996) Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 14: 1922-1927.
6. Biroccio A, Benassi B, D'Agnano I, D'Angelo C, Buglioni S, Mottolese M, Ricciotti A, Citro G, Cosimelli M, Ramsay RG, Calabretta B, Zupi G (2001) c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol 158: 1289-1299.
7. Calvo P, Sánchez A, Martínez J et al (1996) Polyester nanocapsules as new topical ocular delivery systems for cyclosporine A. Pharmacol Res 13: 311-315.
8. Chan HS, Gallie BL, Munier FL, Beck Popovic M (2005) Chemotherapy for retinoblastoma. Ophthalmol Clin North Am 18: 55-63.
9. Chévez-Barrios P, Hurwitz M, Louie K, Marcus K, Holcombe V, Schafer P, Aguilar-Cordova C, Hurwitz R (2000) Metastatic and nonmetastatic models of retinoblastoma. Am J Pathol 157: 1405-1412.
10. Coffer PJ, Jin J, Woodgett J (1998) Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 335: 1-13.
11. Cohen J (1993) Apoptosis. Immunol Today 14: 126-130.
12. Corson T, Huang A, Tsao M, Gallie B (2005) KIF14 are a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 24: 4741-4753.
13. Davda J, Labhasetwar V (2002) Characterization of nanoparticle uptake by endothelial cells. Int J Pharm 233: 51-59.
14. Davies L, Gray D, Spiller D, White M, Damato B, Grierson I, Paraoan L (2009) P53 apoptosis mediator PERP: localization, function and caspase activation in uveal melanoma. J Cell Mol Med 13: 1995-2007.
15. Diepold R, Kreuter J, Himber J, Gurny R, Lee VH, Robinson JR, Saettone MF, Schnaudigel OE (1989) Comparison of different models for the testing of pilocarpine eyedrops using conventional eyedrops and a novel depot formulation (nanoparticles). Graefes Arch Clin Exp Ophthalmol 227: 188-193.
16. Douglas KL, Piccirillo CA, Tabrizian M (2008) Cell line-dependent internalization pathways and intracellular trafficking determine transfection efficiency of nanoparticle vectors. Eur J Pharm Biopharm 68: 676-687.
17. Enríquez de Salamanca A, Diebold Y, Calonge M, García-Vazquez C, Callejo S, Vila A, Alonso MJ (2006) Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci 47: 1416-1425.
18. Friend SH, Horowitz JM, Gerber MR, Wang XF, Bogenmann E, Li FP, Weinberg RA (1987) Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc Natl Acad Sci USA 84: 9059-9063.
19. Garcion E, Lamprecht A, Heurtault B, Paillard A, Aubert-Pouessel A, Denizot B, Menei P, JP B (2006) A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Mol Cancer Ther 5: 1710-1722.
20. Gillet J, Efferth T, Steinbach D, Hamels J, de Longueville F, Bertholet V, Remacle J (2004) Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res 15: 8987-8993.
21. Giubellino A, Linehan W, Bottaro D (2009) Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther 9: 785-793.
22. Gross A, Mc Donnell J, Korsmeyer S (1999) Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911.
23. Hande KR (1992) Etoposide pharmacology. Semin Oncol 19: 3-9.
24. Harmia T, Speiser P, Kreuter J (1986) A solid colloidal drug delivery system for the eye: encapsulation of pilocarpin in nanoparticles. J Microencapsul 3: 3-12.
25. Hashizoe M, Ogura Y, Takanashi T, Kunou N, Honda Y, Ikada Y (1997) Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits. Curr Eye Res 16: 633-639.
26. Hildesheim J, Bulavin D, Anver M, Alvord W, Hollander M, Vardanian L, Fornace AJ Jr (2002) Gadd45a protects against UV irradiation-induced skin tumors, and promotes apoptosis and stress signaling via MAPK and p53. Cancer Res 64: 7305-7315.
27. Ioannou YA, Chen FW (1996) Quantitation of DNA fragmentation in apoptosis. Nucleic Acid Res 24: 992-993.
28. Jasti BR, Du J, Vasavada RC (1995) Characterization of thermal behavior of etoposide. Int J Pharmaceu 118: 161-167.
29. Kim J, Kim E, Kim S, Taeg Kyu Kwon T, KS SC (2010) Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation. Carcinogenesis 31: 367-375.
30. Lemoine D, Francois C, Kedzierewicz F, Preat V, Hoffman M, Maincent P (1996) Stability study of nanoparticles of poly(E-caprolactone), poly (d, l-lactide) and poly (d, l-lactide-co-glycolide). Biomaterials 17: 2191-2197.
31. Liu H, Ippolito GC, Wall JK, Niu T, Probst L, Lee BS, Pulford K, Banham AH, Stockwin L, Shaffer AL, Staudt LM, Das C, Dyer MJ, Tucker PW (2006) Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells. Mol Cancer Ther 5: 1-18.
32. Marchal-Heussler L, Sirbat D, Hoffman M, Maincent P (1993) Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery. Pharm Res 10: 386-390.
33. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR (1995) Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182: 1545-1556.
34. Mayer E, Krop I (2010) Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 16: 3526-3532.
35. Misra R, Sahoo SK (2010) Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharmaceu Sci 39: 152-163.
36. Misra R, Acharya S, Dilnawaz F, Sahoo SK (2009) Sustained antibacterial activity of doxycycline-loaded poly(d, l-lactide-co-glycolide) and poly(epsilon-caprolactone) nanoparticles. Nanomedicine (Lond) 4: 519-530.
37. Moutushy M, Mallikarjuna K, Verma RS, Uma M, Krishnakumar S (2010) Genome-wide changes accompanying knock-down of Ep-CAM in retinoblastoma. Mol Vis 16: 828-842.
38. Noh W, Mondesire W, Peng J, Jian W, Zhang H, Dong J (2004) Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10: 1013-1023.
39. Panyam J, Labhasetwar V (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55: 329-347.
40. Panyam J, Labhasetwar V (2004) Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol Pharm 1: 77-84.
41. Panyam J, Williams D, Dash A, Leslie-Pelecky D, Labhasetwar V (2004) Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci 93: 1804-1814.
42. Polzien L, Baljuls A, Rennefahrt U, Fischer A, Schmitz W, Zahedi R, Sickmann A, Metz R, Albert S, Benz R, Hekman M, UR R (2009) Identification of novel in vivo phosphorylation sites of the human proapoptotic protein BAD: pore-forming activity of BAD is regulated by phosphorylation. J Biol Chem 284: 28004-28020.
43. Qaddoumi MG, Gukasyan HJ, Davda J, Labhasetwar V, Kim K-J, H-L LV (2003) Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis. Mol Vis 9: 559-568.
44. Raffaella A, Simona R, Rosanna P, Rita B, Annalisa L, Vincenzo P, Salvatore V, Maria FR (2005) Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 106: 1400-1406.
45. Reddy LH, Adhikari JS, Dwarakanath SR, Sharma RK, Murthy RR (2006) Tumoricidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in Dalton's lymphoma bearing mice. AAPS J 8: E254-E262.
46. Rödel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rödel F (2003) Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 55: 1341-1347.
47. Rodriguez-Galindo CWM, Chantada G, Fu L, Qaddoumi I, Antoneli C, Leal-Leal CST, Barnoya M, Epelman S, Pizzarello L, Kane JR, Barfield R, Merchant TE, Robinson LL, Murphree AL, Chevez-Barrios P, Dyer MA, O'Brien J, Ribeiro RC, Hungerford JHE, Haik BG, Wilimas J (2008) Retinoblastoma: one world, one vision. Pediatrics 122: e763.
48. Sahoo SK, Labhasetwar V (2005) Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2: 373-383.
49. Sahoo SK, Panyam J, Prabha S, Labhasetwar V (2002) Residual polyvinyl alcohol associated with poly(d, l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 82: 105-114.
50. Sahoo SK, Ma W, Labhasetwar V (2004) Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 112: 335-340.
51. Sahoo SK, Dilnawaz F, Krishnakumar S (2008) Nanotechnology in ocular drug delivery. Drug Discov Today 13: 144-151.
52. Shah JC, Chen JR, Chow D (1995) Preformulation study of etoposide: II. Increased solubility and dissolution rate by solid-solid dispersion. Int J Pharm 113: 103-111.
53. Shammas M, Neri P, Koley H, Batchu R, Bertheau R, Munshi V, Prabhala R, Fulciniti M, Tai YT, Treon SP, Goyal RK, Anderson KC, Munshi NC (2006) Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood 108: 2804-2810.
54. Shi YJ, Zeng K, Li GF, Zhang M, Zhu XL, Sun LD, Yang XX (2008) Effects of podophyllotoxin solid lipid nanoparticles on proliferation and apoptosis of cervical carcinoma cells. Nan Fang Yi Ke Da Xue Xue Bao 5: 786-788.
55. Shirazi FH, Bahrami G, Stewart DJ, Tomiak E, Delorme F, Neol D (2001) A rapid reversed phase high performance liquid chromatographic method for determination of etoposide (VP-16) in human plasma. J Pharm Biomed Anal 25: 353-356.
56. Smit EF, Carney DN, Harford P, Sleijfer DT, Postmus PE (1989) A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 44: 631-633.
57. Smith LM, Donaldson SS (1991) Incidence and management of secondary malignancies in patients with retinoblastoma and Ewing's sarcoma. Oncology (Williston Park) 5: 135-141.
58. Snehalatha MVK, Saha RN, Babbar AK, Sharma RK (2008) Etoposide loaded PLGA and PCL nanoparticles II: biodistribution and pharmacokinetics after radiolabeling with Tc-99m. Drug Deliv 15: 277-287.
59. Stahl JM, Sharma A, Cheung M et al (2004) Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64: 7002-7010.
60. Travis LB, Holowaty EJ, Bergfeldt K, Lynch CF, Kohler BA, Wiklund T, Curtis RE, Hall P, Andersson M, Pukkala E, Sturgeon J, Stovall M (1999) Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 340: 351-357.
61. van Quill KR, Dioguardi PK, Tong CT, Gilbert JA, Aaberg TM, Jr GHE, Edelhauser HF, O'Brien JM (2005) Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology 112: 1151-1158.
62. Vandana MSS (2009) Optimization of physicochemical parameters influencing the fabrication of protein-loaded chitosan nanoparticles. Nanomedicine (Lond) 4: 773-785.
63. Wong D, Billington BM, Chignell AH (1987) Pars plana vitrectomy for retinal detachment with unseen retinal holes. Graefe Arch Clin Exp Ophthalmol 225: 269-271.
64. Yadav KSS, Krutika K (2010) Formulation optimization of etoposide loaded PLGA nanoparticles by double factorial design and their evaluation. Curr Drug Deliv 7: 51-64.
65. Yasukawaa T, Ogurac Y, Tabatad Y, Kimurae H, Wiedemanna P, Honda Y (2004) Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res 23: 253-281.
66. Zimmer A, Chetoni P, Saettone M, Zerbe H, Kreuter J (1995) Evaluation of pilocarpine-loaded albumin nanoparticles as controlled drug delivery systems for the eye. II. Co-administration with bioadhesive and viscous polymers. J Cont Rel 33: 31-46.